T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
576
Truist Financial
TFC
$64.7B
| $129M | 0.01% |
2,621,224
-23,453
| -0.9% | -$1.08M |
|
577
Paylocity
PCTY
$7.66B
| $129M | 0.01% |
845,728
-502,910
| -37% | -$74.8M |
|
578
Zurn Elkay Water Solutions
ZWS
$8.4B
| $128M | 0.01% |
2,748,690
+162,065
| +6% | +$7.61M |
|
579
On Holding
ONON
$10.3B
| $127M | 0.01% |
2,738,692
+1,492,917
| +120% | +$64.3M |
|
580
National Fuel Gas
NFG
$7.72B
| $127M | 0.01% |
1,582,782
+1,372,742
| +654% | +$113M |
|
581
Affirm
AFRM
$25.5B
| $126M | 0.01% |
1,697,500
+1,029,646
| +154% | +$74.1M |
|
582
Cavco Industries
CVCO
$4.61B
| $126M | 0.01% |
213,572
+74,542
| +54% | +$42.2M |
|
583
Wave Life Sciences
WVE
$1.07B
| $126M | 0.01% |
7,407,372
+3,362,880
| +83% | +$34.2M |
|
584
General Dynamics
GD
$106B
| $125M | 0.01% |
372,105
+143
| +0% | +$48.8K |
|
585
Futu Holdings
FUTU
$14.5B
| $124M | 0.01% |
755,339
-64,353
| -8% | -$11M |
|
586
Celcuity
CELC
$4.39B
| $124M | 0.01% |
1,240,281
+642,125
| +107% | +$52.8M |
|
587
Petrobras
PBR
$115B
| $123M | 0.01% |
10,389,475
+3,533,479
| +52% | +$43.1M |
|
588
Cytokinetics
CYTK
$10.4B
| $123M | 0.01% |
1,930,119
-436,729
| -18% | -$27.2M |
|
589
Protagonist Therapeutics
PTGX
$9.92B
| $122M | 0.01% |
1,400,738
+180,302
| +15% | +$14.8M |
|
590
Toast
TOST
$19.9B
| $121M | 0.01% |
3,414,051
-1,807,440
| -35% | -$65.2M |
|
591
HealthEquity
HQY
$8.75B
| $121M | 0.01% |
1,317,719
-216,011
| -14% | -$20.7M |
|
592
Dell
DELL
$320B
| $121M | 0.01% |
958,908
+181
| +0% | +$25.5K |
|
593
Birkenstock
BIRK
$7.68B
| $121M | 0.01% |
2,950,380
+25,585
| +0.9% | +$1.08M |
|
594
Impinj
PI
$5.42B
| $121M | 0.01% |
692,596
+18,263
| +3% | +$3.25M |
|
595
Alamos Gold
AGI
$13.7B
| $119M | 0.01% |
3,073,897
-717,630
| -19% | -$25M |
|
596
Horace Mann Educators
HMN
$2.09B
| $118M | 0.01% |
2,549,210
+1,393
| +0.1% | +$63.1K |
|
597
Darden Restaurants
DRI
$25.5B
| $118M | 0.01% |
638,757
-1,973
| -0.3% | -$360K |
|
598
VSE Corp
VSEC
$6.66B
| $117M | 0.01% |
676,713
+178,013
| +36% | +$30.4M |
|
599
Structure Therapeutics
GPCR
$3.83B
| $116M | 0.01% |
1,671,138
+1,381,745
| +477% | +$56.4M |
|
|
KMTS
600
Kestra Medical Technologies
KMTS
$1.62B
| $116M | 0.01% |
4,369,429
+2,529,851
| +138% | +$65.2M |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.